Want to see DRMA full AI Analyst Report?
Top Page
Dermata Therapeutics
(NASDAQ:DRMA)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.88
▼(-48.66% Downside)
Action:Reiterated
Date:10/16/26
The score is primarily weighed down by weak financial performance—no revenue, ongoing losses, and sustained cash burn—despite the benefit of having no debt. Technicals also remain bearish with the stock trading below key moving averages and a negative MACD. Corporate events modestly improve the outlook via added funding and a first commercial product launch, but they do not yet offset the current financial and trend risks.
Positive Factors
Debt-Free Balance Sheet
Zero reported debt removes interest expense and reduces solvency pressure while Dermata funds development and commercialization. That gives the company more flexibility than a similarly loss-making biotech, although the benefit is constrained by its small and declining equity base.
Negative Factors
No Reported Revenue
DRMA has reported no revenue across annual periods and TTM, so the business has not yet demonstrated product-market monetization or operating leverage. Until commercial sales scale, continued R&D and corporate spending must be funded without an established recurring revenue stream.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
Zero reported debt removes interest expense and reduces solvency pressure while Dermata funds development and commercialization. That gives the company more flexibility than a similarly loss-making biotech, although the benefit is constrained by its small and declining equity base.
Read all positive factors
Dermata Therapeutics (DRMA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.87M
Dividend YieldN/A
Average Volume (3M)5.85M
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue GrowthN/A
EPS Growth88.77%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.39
Shares Outstanding4,955,207
10 Day Avg. Volume17,496,973
30 Day Avg. Volume5,847,011
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.35
Price to Sales (P/S)0.00
P/FCF Ratio-0.28
Enterprise Value/Market Cap0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.09
Forecast
1Y Price Target
$4.00Price Target Upside132.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.21
Revenue Forecast (FY)$15.00M
Dermata Therapeutics Business Overview & Revenue Model
Company Description
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment ...
How the Company Makes Money
As a clinical-stage biotechnology company, Dermata Therapeutics has not established a durable, recurring commercial revenue base from product sales. Its ability to generate revenue is primarily tied to external funding and, potentially, to future ...
Dermata Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
9
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -8.49M | -7.77M | -12.29M | 246.91K | -9.67M | -7.86M |
| Net Income | -8.37M | -7.56M | -12.29M | -7.79M | -9.61M | -7.90M |
Balance Sheet | ||||||
| Total Assets | 5.32M | 7.86M | 3.53M | 7.98M | 6.94M | 11.62M |
| Cash, Cash Equivalents and Short-Term Investments | 4.41M | 7.52M | 3.16M | 7.44M | 6.24M | 10.80M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.83M | 1.64M | 1.97M | 1.62M | 922.63K | 1.52M |
| Stockholders Equity | 3.49M | 6.22M | 1.56M | 6.36M | 6.02M | 10.11M |
Cash Flow | ||||||
| Free Cash Flow | -8.14M | -7.76M | -11.16M | -6.41M | -8.83M | -5.69M |
| Operating Cash Flow | -8.03M | -7.76M | -11.16M | -6.41M | -8.83M | -5.69M |
| Investing Cash Flow | -110.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 6.08M | 12.12M | 6.89M | 7.61M | 4.28M | 15.96M |
Dermata Therapeutics Technical Analysis
Negative
1.72
Price Trends
1.17
Negative
1.21
Negative
1.35
Negative
Market Momentum
-0.10
Positive
36.10
Neutral
36.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DRMA, the sentiment is Negative. The current price of 1.72 is above the 20-day moving average (MA) of 0.97, above the 50-day MA of 1.17, and above the 200-day MA of 1.35, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 36.10 is Neutral, neither overbought nor oversold. The STOCH value of 36.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DRMA.
Dermata Therapeutics Risk Analysis
Dermata Therapeutics disclosed 87 risk factors in its most recent earnings report. Dermata Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dermata Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
DRMA
Dermata Therapeutics
0.78
-3.29
-80.81%
REVB
Revelation Biosciences
3.79
-32.33
-89.51%
CERO
CERo Therapeutics Holdings
0.01
-1.87
-99.47%
PBM
Psyence Biomedical
4.17
-16.21
-79.56%
AZTR
Azitra Inc
0.07
-0.48
-87.00%
Dermata Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Dermata Therapeutics Announces Private Placement to Fund DTC Pivot
Positive
Aug 17, 2026
On August 16, 2026, Dermata Therapeutics entered into definitive securities purchase agreements for a private placement of 2,293,608 shares of common stock or pre-funded warrants, along with Series E and short-term Series F warrants, priced at-the...
Business Operations and StrategyProduct-Related Announcements
Dermata Therapeutics Launches Tome Foundational Skincare Line
Positive
Aug 5, 2026
On August 5, 2026, Dermata Therapeutics, Inc. announced plans to launch its first commercial product, Tome Foundational Treatment, marking a strategic move into revenue-generating consumer skincare. The regimen-based set, comprising four once-week...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.